FDA Approves Moderna's mRNA Flu Vaccine for Older Adults

Why it matters locally: The approval of Moderna's mRNA flu vaccine for adults aged 50 and older will impact public health initiatives across Georgia, particularly as local healthcare providers and public health agencies plan for upcoming flu seasons. The Georgia Department of Public Health will likely incorporate this new option into its vaccination campaigns.

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based influenza vaccine, mFlusiva. This approval specifically covers adults aged 50 and older. mFlusiva represents a new type of flu shot entering the market. Moderna developed the vaccine using messenger RNA (mRNA) technology. This technology differs from traditional vaccine methods, which often use inactivated or weakened forms of the virus. Regulators granted approval for mFlusiva following a review of clinical data. The vaccine aims to protect against seasonal influenza. The target demographic for this shot includes individuals at higher risk of complications from the flu.